Compare ABUS & CVLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABUS | CVLG |
|---|---|---|
| Founded | 2005 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 836.0M | 867.7M |
| IPO Year | 2008 | 1996 |
| Metric | ABUS | CVLG |
|---|---|---|
| Price | $4.35 | $29.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.50 |
| AVG Volume (30 Days) | ★ 6.3M | 123.2K |
| Earning Date | 11-12-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 0.96% |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ 0.84 | 0.49 |
| Revenue | $14,083,000.00 | ★ $705,007,000.00 |
| Revenue This Year | $1,208.75 | $13.08 |
| Revenue Next Year | N/A | $9.15 |
| P/E Ratio | ★ $4.98 | $59.94 |
| Revenue Growth | ★ 128.21 | 5.12 |
| 52 Week Low | $3.50 | $18.00 |
| 52 Week High | $5.45 | $49.88 |
| Indicator | ABUS | CVLG |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 25.34 |
| Support Level | $4.17 | $23.98 |
| Resistance Level | $4.57 | $30.09 |
| Average True Range (ATR) | 0.18 | 1.00 |
| MACD | -0.02 | -0.21 |
| Stochastic Oscillator | 15.43 | 1.63 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Covenant Logistics Group Inc together with its wholly-owned subsidiaries, offers truckload transportation and freight brokerage services to customers throughout the continental United States. The company's reportable segments include Expedited, Dedicated Services, Managed Freight, and Warehousing. The expedited segment provides truckload services to customers with high service freight and delivery standards. Dedicated segment provides customers with committed truckload capacity over contracted periods with the goal of three to five years in length. The Managed Freight segment includes brokerage services and TMS. The warehousing segment provides day-to-day warehouse management services to customers who have chosen to outsource this function.